One Stop Solution For In-Depth Market Research Reports

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market (Product: Buphenyl, Ravicti, Ammonul, Dietary Supplements, and Others; Route of Administration: Oral and Intravenous; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030


Product Code : TMRHC00111239
Survey : Transparency Market Research
Publish On : 20, May, 2022
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5795 / Question Form
5 User USD8795 / Question Form
Enterprise User USD11795 / Question Form

Abbott
Nutricia (Danone Group)
Mead Johnson (Reckitt Benckiser)
Horizon Therapeutics plc
Nestlé
Bausch Health Companies, Inc.
Ultragenyx Pharmaceutical Inc.
Arcturus Therapeutics, Inc.
Acer Therapeutics

[Report Description]

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Overview

 

 


  • Ornithine transcarbamylase deficiency, a highly common urea cycle disorder and rare X-linked genetic disorder, is characterized by partial or a complete lack of enzyme ornithine transcarbamylase (OTC)

  • OTC is one of six enzymes that play a role in breakdown and removal of nitrogen in the body, a process known as the urea cycle

  • OTC deficiency is a genetic disorder characterized by a complete or partial lack of the enzyme ornithine transcarbamylase (OTC). It is an abnormal gene on the X chromosome and manifests mostly in males.

  • Both males and females may develop symptoms of OTC deficiency during childhood. Females who have a defective gene present on one of their X chromosomes are carriers for the disorder.


  •  

 

 

 

 

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Drivers

 

 

 

 


  • Rising prevalence of OTC deficiency and development of new therapies for the treatment of OTC deficiency are major factors boosting the global ornithine transcarbamylase (OTC) deficiency treatment market

  • For instance, according to Orphanet, the estimated prevalence of ornithine transcarbamylase deficiency ranges between 1/56,500 and 1/113,000 live births across the world

  • Favorable reimbursement scenario and patient assistance programs provided by various international as well as regional organizations are also major drivers of the global Ornithine Transcarbamylase (OTC) deficiency treatment market

  • Patient compliance is affected due to bitter taste and foul odor of products. Hence, research and development is being carried out to develop new formulations of this drug in order to overcome such serious issues.

  • Consequently, formulation modification for better patient compliance also propels the global ornithine transcarbamylase (OTC) deficiency treatment market


  •  

 

 

 

 

Market Segmentation: Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

 

 

 

 


  • In terms of product, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into Buphenyl, Ravicti, Ammonul, dietary supplements, and others

  • Based on route of administration, the global ornithine transcarbamylase (OTC) deficiency treatment market has been bifurcated into oral and intravenous

  • In terms of distribution channel, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies

  • Each of the ornithine transcarbamylase (OTC) deficiency treatment market segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights

  • The ornithine transcarbamylase (OTC) deficiency treatment market report provides current and future revenues (US$ Mn) for each of the segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030 along with market size estimations.


  •  

 

 

 

 

Regional Overview: Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

 

 

 

 


  • In terms of region, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

  • North America dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019, and the trend is projected to continue during the forecast period

  • The current and future sizes of the ornithine transcarbamylase (OTC) deficiency treatment market, in terms of value (US$ Mn), of regional markets and their major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030

  • The study also offers a list of recommendations, highlights, and useful insights of the market, which would help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process


  •  

 

 

 

 

Major Players

 

 

 

 


  • The ornithine transcarbamylase (OTC) deficiency treatment market report concludes with the company profiles section that includes key information about the major players in the market

  • Key players analyzed in the ornithine transcarbamylase (OTC) deficiency treatment market report are -

    • Abbott

    • Nutricia (Danone Group)

    • Mead Johnson (Reckitt Benckiser)

    • Horizon Therapeutics plc

    • Nestlé

    • Bausch Health Companies, Inc.

    • Ultragenyx Pharmaceutical Inc.

    • Arcturus Therapeutics, Inc.

    • Acer Therapeutics


    •  

  • Each of these players has been profiled in the global ornithine transcarbamylase (OTC) deficiency treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments


  •  

 

 

 

 

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Scope of the Report

 

 

 

 

The report on the global ornithine transcarbamylase (OTC) deficiency treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall market revenue of the global ornithine transcarbamylase (OTC) deficiency treatment market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global ornithine transcarbamylase (OTC) deficiency treatment market for the forecast period.

 

 

 

 

The report has been prepared after extensive primary and secondary research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global ornithine transcarbamylase (OTC) deficiency treatment market.

 

 

 

 

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the global ornithine transcarbamylase (OTC) deficiency treatment market.

 

 

 

 

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global ornithine transcarbamylase (OTC) deficiency treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global ornithine transcarbamylase (OTC) deficiency treatment market.

 

 

 

 

The report delves into the competitive landscape of the global ornithine transcarbamylase (OTC) deficiency treatment market. Key players operating in the global ornithine transcarbamylase (OTC) deficiency treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global ornithine transcarbamylase (OTC) deficiency treatment market that have been profiled in this report.

 

 

 

 

Key Questions Answered in Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Report

 

 

 

 


  • What is the sales/revenue generated by each product, route of administration, and distribution channel segment of the global ornithine transcarbamylase (OTC) deficiency treatment market across all regions during the forecast period?

  • What are the opportunities in the global ornithine transcarbamylase (OTC) deficiency treatment market?

  • What are the major drivers, restraints, opportunities, and threats in the market?

  • Which region is likely to expand at the fastest CAGR during the forecast period?

  • Which ornithine transcarbamylase (OTC) deficiency treatment segments are expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?

  • What is the market share or position of different companies operating in the global market in 2019?


  •  

 

 

 

 

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Research Objectives and Research Approach

 

 

 

 

The comprehensive report on the global ornithine transcarbamylase (OTC) deficiency treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, disease prevalence in key countries, Overview of Diagnostics Approach for OTC Deficiency, standard guidelines for approval of drugs, and impact of COVID-19 in global ornithine transcarbamylase (OTC) deficiency treatment market have been provided.

 

 

 

 

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

 

 

 

 

The report analyzes the global ornithine transcarbamylase (OTC) deficiency treatment market in terms of product, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ornithine transcarbamylase (OTC) deficiency treatment market.

 

 

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Product Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, 2018–2030

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Disease Prevalence & Incidence Rate globally with key countries

5.2. Pipeline Analysis

5.3. Standard Guidelines for Approval of Drugs

5.4. Overview of Diagnostics approach for OTC Deficiency

5.5. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Product

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

6.3.1. Buphenyl

6.3.2. Ravicti

6.3.3. Ammonul

6.3.4. Dietary Supplements

6.3.5. Others

6.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product

7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

7.3.1. Oral

7.3.2. Intravenous

7.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration

8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel

9. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Region

10. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

10.2.1. Buphenyl

10.2.2. Ravicti

10.2.3. Ammonul

10.2.4. Dietary Supplements

10.2.5. Others

10.3. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

10.3.1. Oral

10.3.2. Intravenous

10.4. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country, 2018–2030

10.5.1. U.S.

10.5.2. Canada

10.6. Market Attractiveness Analysis

10.6.1. By Product

10.6.2. By Route of Administration

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

11.2.1. Buphenyl

11.2.2. Ravicti

11.2.3. Ammonul

11.2.4. Dietary Supplements

11.2.5. Others

11.3. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

11.3.1. Oral

11.3.2. Intravenous

11.4. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis

11.6.1. By Product

11.6.2. By Route of Administration

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

12.2.1. Buphenyl

12.2.2. Ravicti

12.2.3. Ammonul

12.2.4. Dietary Supplements

12.2.5. Others

12.3. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

12.3.1. Oral

12.3.2. Intravenous

12.4. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis

12.6.1. By Product

12.6.2. By Route of Administration

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

13.2.1. Buphenyl

13.2.2. Ravicti

13.2.3. Ammonul

13.2.4. Dietary Supplements

13.2.5. Others

13.3. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

13.3.1. Oral

13.3.2. Intravenous

13.4. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis

13.6.1. By Product

13.6.2. By Route of Administration

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

14.2.1. Buphenyl

14.2.2. Ravicti

14.2.3. Ammonul

14.2.4. Dietary Supplements

14.2.5. Others

14.3. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

14.3.1. Oral

14.3.2. Intravenous

14.4. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis

14.6.1. By Product

14.6.2. By Route of Administration

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player – Competition Matrix (By Tier and Size of companies)

15.2. Market Share/Position Analysis, by Company (2019)

15.3. Company Profiles

15.3.1. Abbott

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Company Financials

15.3.1.3. Growth Strategies

15.3.1.4. SWOT Analysis

15.3.2. Nutricia (Danone Group)

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Company Financials

15.3.2.3. Growth Strategies

15.3.2.4. SWOT Analysis

15.3.3. Mead Johnson (Reckitt Benckiser)

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Company Financials

15.3.3.3. Growth Strategies

15.3.3.4. SWOT Analysis

15.3.4. Horizon Therapeutics plc

15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.4.2. Company Financials

15.3.4.3. Growth Strategies

15.3.4.4. SWOT Analysis

15.3.5. Nestlé

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Company Financials

15.3.5.3. Growth Strategies

15.3.5.4. SWOT Analysis

15.3.6. Bausch Health Companies, Inc.

15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.6.2. Company Financials

15.3.6.3. Growth Strategies

15.3.6.4. SWOT Analysis

15.3.7. Ultragenyx Pharmaceutical Inc.

15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.7.2. Company Financials

15.3.7.3. Growth Strategies

15.3.7.4. SWOT Analysis

15.3.8. Arcturus Therapeutics, Inc.

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Company Financials

15.3.8.3. Growth Strategies

15.3.8.4. SWOT Analysis

15.3.9. Acer Therapeutics

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Company Financials

15.3.9.3. Growth Strategies

15.3.9.4. SWOT Analysis

Shibuya data count

Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.

Recommended reports

+